Ciprofloxacin-induced torsade de pointes

International Journal of Cardiology

Volumn 113, Issue 2, 2006, Pages 239-241

  Casey Flanagan, M ^a   Mitchell, Eric S ^a   Haigney, Mark C P ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Ciprofloxacin; QT interval; Torsade de pointes

Indexed keywords

CIPROFLOXACIN;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; PNEUMONIA; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

ADULT; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; PNEUMONIA, BACTERIAL; TORSADES DE POINTES;

EID: 33751064084     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.08.048     Document Type: Article

References (7)

1. Liu B.A., and Juurlink D.N. Drugs and the QT interval-caveat doctor. N Engl J Med 351 (2004) 1053-1056
2. Long V.S. QT syndromes and torsade de pointes. Lancet 354 (1999) 1628-1633
3. Frothingham R. Rate of torsade de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 21 (2001) 1468-1472
4. Amankwa K., Drishnan S.C., and Tisdale J.E. Torsade de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 75 3 (2004) 242-247
5. Ciprofloxacin intravenous infusion [Package Insert] Bayer laboratories (2004), Bayer Laboratories, West Haven, CT
6. Ciprofloxacin oral suspension [Package Insert] Bayer laboratories (2002), Bayer Laboratories, West Haven, CT
7. Bertino Jr. J.S., Owens R.C., Carnes T.D., and Iannini P.B. Gatifloxacin-associated corrected QT interval prolongation, Torsade de Pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 34 (2002) 861-863